Purple Biotech (PPBT) Capital Expenditures (2017 - 2023)
Purple Biotech (PPBT) reported Capital Expenditures of $6000.0 for Q4 2023, down 88.46% year-over-year from $52000.0 in Q4 2022, and up 500.0% quarter-over-quarter from $1000.0 in Q3 2023.
Purple Biotech (PPBT) Capital Expenditures (2017 - 2023) Analysis & Trends
Purple Biotech (PPBT) has 7 years of Capital Expenditures data on file, last reported at $6000.0 in Q4 2023.
- Capital Expenditures for Q4 2023 came in at $6000.0, down 88.46% year-over-year; the trailing twelve-month figure through Dec 2023 was $3000.0 (down 88.46% YoY), and the FY2025 annual result was $3000.0, changed N/A from the prior year.
- Capital Expenditures climbed to $6000.0 in Q4 2023 per PPBT's latest filing, from $1000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $52000.0 in Q4 2022 and troughed at -$156000.0 in Q4 2020.
- A 5-year average of -$17928.6 and a median of -$6000.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2020 and 2022: Capital Expenditures tumbled 5100.0% in 2020, then surged 966.67% in 2022.
- A 5-year view of Capital Expenditures shows it stood at -$3000.0 in 2019, then plunged by 5100.0% to -$156000.0 in 2020, then jumped by 96.15% to -$6000.0 in 2021, then surged by 966.67% to $52000.0 in 2022, then plunged by 88.46% to $6000.0 in 2023.
- Business Quant data shows PPBT's Capital Expenditures at $6000.0 in Q4 2023, $1000.0 in Q3 2023, and -$1000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -63,220.27 |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | 52,000.00 |
| Dec 31, 2022 | 52,000.00 |
| Sep 30, 2022 | -6,000.00 |
| Sep 30, 2022 | -6,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Mar 31, 2022 | -14,000.00 |
| Mar 31, 2022 | -14,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Sep 30, 2021 | -6,000.00 |